Aeglea Bio Therapeutics (NASDAQ:AGLE) released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04), MarketWatch Earnings reports.
NASDAQ AGLE opened at $6.52 on Friday. Aeglea Bio Therapeutics has a 12 month low of $6.31 and a 12 month high of $12.00. The company has a market cap of $188.97 million, a price-to-earnings ratio of -3.06 and a beta of 0.89.
In related news, CEO Anthony G. Quinn acquired 26,592 shares of the business’s stock in a transaction on Wednesday, May 22nd. The stock was acquired at an average cost of $6.77 per share, with a total value of $180,027.84. Following the acquisition, the chief executive officer now directly owns 304,135 shares in the company, valued at approximately $2,058,993.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Anthony G. Quinn acquired 8,989 shares of the business’s stock in a transaction on Monday, May 20th. The shares were bought at an average cost of $6.56 per share, with a total value of $58,967.84. Following the completion of the acquisition, the chief executive officer now owns 304,135 shares in the company, valued at $1,995,125.60. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 48,055 shares of company stock worth $322,636. 18.30% of the stock is owned by company insiders.
A number of research firms have commented on AGLE. HC Wainwright began coverage on shares of Aeglea Bio Therapeutics in a research note on Tuesday, May 21st. They set a “buy” rating and a $20.00 target price on the stock. JPMorgan Chase & Co. began coverage on shares of Aeglea Bio Therapeutics in a research note on Thursday, March 21st. They set an “overweight” rating and a $14.00 target price on the stock. Finally, ValuEngine cut shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 9th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.00.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Rockland Register and is owned by of Rockland Register. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://rocklandregister.com/2019/05/31/aeglea-bio-therapeutics-agle-issues-earnings-results.html.
About Aeglea Bio Therapeutics
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Read More: Book Value Per Share – BVPS
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.